NCT03604406View on ClinicalTrials.gov

The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 8, 2014

Primary Completion Date

June 30, 2024

Study Completion Date

February 28, 2026

Conditions
Herpes ZosterInflammatory DiseaseRheumatoid Arthritis
Interventions
BIOLOGICAL

Varicella Zoster Vaccine

live-attenuated vaccine to prevent herpes zoster

OTHER

Placebo Injection

Saline solution injection

BIOLOGICAL

Varicella Zoster Vaccine

non-live vaccine to prevent herpes zoster

Trial Locations (5)

37343

Arthritis Associates, Hixson

55121

St. Paul Rheumatology, Eagan

83702

St. Luke's Health System, Boise

88101

Jayashree Sinha, MD, Clovis

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Kevin Winthrop

OTHER

NCT03604406 - The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept | Biotech Hunter | Biotech Hunter